<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Ophthalmology Reports</journal-id><journal-title-group><journal-title xml:lang="en">Ophthalmology Reports</journal-title><trans-title-group xml:lang="ru"><trans-title>Офтальмологические ведомости</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1998-7102</issn><issn publication-format="electronic">2412-5423</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">568953</article-id><article-id pub-id-type="doi">10.17816/OV568953</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Experimental trials</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Экспериментальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Corneal changes after fulguration and cross-linking in experiment</article-title><trans-title-group xml:lang="ru"><trans-title>Изменения роговицы после фульгурации и кросслинкинга в эксперименте</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title/></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3700-8255</contrib-id><contrib-id contrib-id-type="spin">3416-3915</contrib-id><name-alternatives><name xml:lang="en"><surname>Boutaba</surname><given-names>Rafik</given-names></name><name xml:lang="ru"><surname>Бутаба</surname><given-names>Рафик</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>dr.rafik_boutaba@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4360-793X</contrib-id><contrib-id contrib-id-type="spin">1603-8931</contrib-id><name-alternatives><name xml:lang="en"><surname>Trufanov</surname><given-names>Sergey V.</given-names></name><name xml:lang="ru"><surname>Труфанов</surname><given-names>Сергей Владимирович</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>д-р мед. наук</p></bio><email>trufanov05@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5187-1047</contrib-id><contrib-id contrib-id-type="spin">4297-6543</contrib-id><name-alternatives><name xml:lang="en"><surname>Riks</surname><given-names>Inna A.</given-names></name><name xml:lang="ru"><surname>Рикс</surname><given-names>Инна Александровна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>riks0503@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0421-1804</contrib-id><name-alternatives><name xml:lang="en"><surname>Ezugbaya</surname><given-names>Maggie</given-names></name><name xml:lang="ru"><surname>Эзугбая</surname><given-names>Мэгги</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>maggie-92@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-8888-4135</contrib-id><contrib-id contrib-id-type="spin">2533-2084</contrib-id><name-alternatives><name xml:lang="en"><surname>Yukina</surname><given-names>Galina Yu.</given-names></name><name xml:lang="ru"><surname>Юкина</surname><given-names>Галина Юрьевна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Biology), Assistant Professor</p></bio><bio xml:lang="ru"><p>канд. биол. наук, доцент</p></bio><email>pipson@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5521-7248</contrib-id><contrib-id contrib-id-type="spin">2115-9041</contrib-id><name-alternatives><name xml:lang="en"><surname>Sukhorukova</surname><given-names>Elena G.</given-names></name><name xml:lang="ru"><surname>Сухорукова</surname><given-names>Елена Геннадиевна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>len48@inbox.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3766-2211</contrib-id><contrib-id contrib-id-type="spin">9794-4692</contrib-id><name-alternatives><name xml:lang="en"><surname>Papanyan</surname><given-names>Sanasar S.</given-names></name><name xml:lang="ru"><surname>Папанян</surname><given-names>Санасар Сурикович</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>Dr.papanyan@yandex.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5184-3775</contrib-id><name-alternatives><name xml:lang="en"><surname>Nikolaenko</surname><given-names>Svetlana L.</given-names></name><name xml:lang="ru"><surname>Николаенко</surname><given-names>Светлана Леонидовна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>nikolaenkos@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5458-4329</contrib-id><name-alternatives><name xml:lang="en"><surname>Gorchakova</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Горчакова</surname><given-names>Ольга Владимировна</given-names></name><name xml:lang="zh"><surname></surname><given-names></given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>gorchakova-spmu@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Academician I.P. Pavlov First St. Petersburg State Medical University</institution></aff><aff><institution xml:lang="ru">Первый Санкт-Петербургский государственный медицинский университет им. акад. И.П. Павлова</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Diagnostic Center No. 7 (ocular)</institution></aff><aff><institution xml:lang="ru">Диагностический центр № 7 (глазной)</institution></aff><aff><institution xml:lang="zh"></institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2024-01-12" publication-format="electronic"><day>12</day><month>01</month><year>2024</year></pub-date><volume>16</volume><issue>4</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><issue-title xml:lang="zh"/><fpage>67</fpage><lpage>77</lpage><history><date date-type="received" iso-8601-date="2023-08-31"><day>31</day><month>08</month><year>2023</year></date><date date-type="accepted" iso-8601-date="2023-10-14"><day>14</day><month>10</month><year>2023</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2024, Эко-Вектор</copyright-statement><copyright-statement xml:lang="zh">Copyright ©; 2024,</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2027-01-12"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref></license></permissions><self-uri xlink:href="https://journals.eco-vector.com/ov/article/view/568953">https://journals.eco-vector.com/ov/article/view/568953</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND:</bold> Severe progressive forms of infectious keratitis are often associated with the risk of violation of the structural integrity of the eyeball and the development of endophthalmitis. In the presence of negative dynamics against the background of conservative etiotropic therapy for severe keratitis, it is advisable to use surgical methods of treatment. The combination of two surgical methods of influencing a pharmacoresistant infectious process in the cornea — cross-linking and fulguration — is promising and requires further investigation.</p> <p><bold>AIM:</bold> In the experiment, to evaluate the effect on the corneal tissue of various modes of direct current fulguration, as well as in combination with cross-linking as well.</p> <p><bold>MATERIALS AND METHODS:</bold> An <italic>in vivo</italic> experimental study was carried out on 19 rabbits (38 eyes) of the Soviet Chinchilla breed, the average body weight of the animals was 2.5–4.0 kg. Depending on the stage of the study, the type and power of exposure during fulguration, the rabbits were divided into 3 groups.</p> <p><bold>RESULTS:</bold> When the cornea was exposed to fulguration in mode 5, the changes covered only 10–15 % of the anterior stroma, about 50 μm, and both clinically and histologically were not sufficient. When exposed to mode 6 and 7 after 3 months, changes in the stromal structure extended by about 150 µm. When using mode 8, there was a slight proliferation of connective tissue between the Descemet’s membrane and the endothelium. The combination of cross-linking with fulguration made it possible to obtain a more compact structure of the anterior layers of the corneal stroma and stability of the epithelium.</p> <p><bold>CONCLUSIONS:</bold> Fulguration may be a relatively safe treatment for the cornea in pharmacoresistant progressive keratitis. Fulguration and corneal cross-linking can potentiate each other’s effect. Fulguration mode 7 (1.5 W) is optimal at corneal exposition for the eradication of infectious agents.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Актуальность</bold>.<italic> </italic>Тяжёлые прогрессирующие формы инфекционного кератита часто сопряжены с риском нарушения структурной целостности глазного яблока и развитием эндофтальмита. При наличии отрицательной динамики на фоне консервативной этиотропной терапии при тяжёлом кератите целесообразно использовать хирургические методы лечения. Комбинация двух хирургических методов воздействия на фармакорезистентный инфекционный процесс в роговице — кросслинкинга и фульгурации — является перспективным и требует дальнейшего изучения.</p> <p><bold>Цель</bold> — в эксперименте оценить воздействие на ткани роговицы различных режимов фульгурации постоянным током, в том числе в комбинации с кросслинкингом.</p> <p><bold>Материалы и методы.</bold><bold> </bold>Экспериментальное исследование <italic>in vivo</italic> было проведено на 19 кроликах (38 глаз) породы советская шиншилла, средняя масса тела животных составила 2,5–4,0 кг. В зависимости от этапа исследования, вида и мощности воздействия при фульгурации кролики были разделены на 3 группы.</p> <p><bold>Результаты.</bold> При воздействии на роговицу в режиме 5 фульгурации изменения охватывали лишь 10–15 % передней стромы, около 50 мкм, и как клинически, так и гистологически были недостаточными. При воздействии в режиме 6 и 7 через 3 мес. изменения стромальной структуры распространялись примерно на 150 мкм. При использовании режима 8 между десцеметовой мембраной и эндотелием отмечалось незначительное разрастание соединительной ткани. Сочетание кросслинкинга с фульгурацией позволило получить более компактную структуру передних слоёв стромы роговицы и стабильность эпителия.</p> <p><bold>Выводы.</bold> Фульгурация может быть относительно безопасным способом воздействия на роговицу при фармакорезистентных прогрессирующих кератитах. Фульгурация и кросслинкинг роговицы могут потенцировать эффект друг друга. Режим фульгурации 7 (1,5 Вт) оптимален при воздействии на роговицу для эрадикации инфекционных агентов.</p></trans-abstract><trans-abstract xml:lang="zh"><p/></trans-abstract><kwd-group xml:lang="en"><kwd>cornea</kwd><kwd>cross-linking (PACK-CXL)</kwd><kwd>fulguration</kwd><kwd>pharmacoresistant infectious keratitis</kwd><kwd>cornea</kwd><kwd>morphological analysis</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>кросслиникнг (PACK-CXL)</kwd><kwd>фульгурация</kwd><kwd>фармакорезистентные инфекционные кератиты</kwd><kwd>роговица</kwd><kwd>морфологический анализ</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">Raj A, Bahadur H, Dhasmana R. Outcome of therapeutic penetrating keratoplasty in advanced infectious keratitis. J Curr Ophthalmol. 2018;30(4):315–332. DOI: 10.1016/j.joco.2018.04.0017</mixed-citation><mixed-citation xml:lang="ru">Raj A., Bahadur H., Dhasmana R. Outcome of therapeutic penetrating keratoplasty in advanced infectious keratitis // J Curr Ophthalmol. 2018. Vol. 30, No. 4. P. 315–332. DOI: 10.1016/j.joco.2018.04.0017</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">Tuli S, Gray M. Surgical management of corneal infections. Curr Opin Ophthalmol. 2016;27(4):340–347. DOI: 10.1097/ICU.0000000000000274</mixed-citation><mixed-citation xml:lang="ru">Tuli S., Gray M. Surgical management of corneal infections // Curr Opin Ophthalmol. 2016. Vol. 27, No. 4. P. 340–347. DOI: 10.1097/ICU.0000000000000274</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">Trufanov SV, Shakhbazyan NP, Zaitsev AV, Rozinova VN. Surgical management of infectious keratitis. The Russian Annals of Ophthalmology. 2021;137(4):128135. (In Russ.) DOI: 10.17116/oftalma2021137041128</mixed-citation><mixed-citation xml:lang="ru">Труфанов С.В., Шахбазян Н.П., Зайцев А.В., Розинова В.Н. Хирургические методы лечения инфекционных кератитов // Вестник офтальмологии. 2021. Т. 137, № 4. С. 128–135. DOI: 10.17116/oftalma2021137041128</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">Trufanov SV, Zaitsev AV, Shakhbazyan NP. Crosslinking and fulguration in the treatment of Acanthamoebic keratitis. Ophthalmology in Russia. 2020;17(4):725–732. (In Russ.) DOI: 10.18008/1816-5095-2020-4-725-732</mixed-citation><mixed-citation xml:lang="ru">Труфанов С.В., Зайцев А.В., Шахбазян Н.П. Кросслинкинг и фульгурация в лечении акантамебного кератита // Офтальмология. 2020. Т. 17, № 4. С. 725–732. DOI: 10.18008/1816-5095-2020-4-725-732</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">Tsugita A, Okada Y, Uehara K. Photosensitized inactivation of ribonucleic acids in the presence of riboflavin. Biochim Biophys Acta. 1965;103(2):360–363. DOI: 10.1016/0005-2787(65)90182-6</mixed-citation><mixed-citation xml:lang="ru">Tsugita A., Okada Y., Uehara K. Photosensitized inactivation of ribonucleic acids in the presence of riboflavin // Biochim Biophys Acta. 1965. Vol. 103, No. 2. P. 360–363. DOI: 10.1016/0005-2787(65)90182-6</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfus Apher Sci. 2006;35(1):5–17. DOI: 10.1016/j.transci.2006.01.007</mixed-citation><mixed-citation xml:lang="ru">Goodrich R.P., Edrich R.A., Li J., Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends // Transfus Apher Sci. 2006. Vol. 35, No. 1. P. 5–17. DOI: 10.1016/j.transci.2006.01.007</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">Marschner S, Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light. Transfus Med Hemother. 2011;38(1):8–18. DOI: 10.1159/000324160</mixed-citation><mixed-citation xml:lang="ru">Marschner S., Goodrich R. Pathogen reduction technology treatment of platelets, plasma and whole blood using riboflavin and UV light // Transfus Med Hemother. 2011. Vol. 38, No. 1. P. 8–18. DOI: 10.1159/000324160</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">Ruane PH, Edrich R, Gampp D, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion. 2004;44(6):877–885. DOI: 10.1111/j.1537-2995.2004.03355</mixed-citation><mixed-citation xml:lang="ru">Ruane P.H., Edrich R., Gampp D., et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light // Transfusion. 2004. Vol. 44, No. 6. P. 877–885. DOI: 10.1111/j.1537-2995.2004.03355</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">Reddy HL, Dayan AD, Cavagnaro J, et al. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev. 2008;22(2):133–153. DOI: 10.1016/j.tmrv.2007.12.003</mixed-citation><mixed-citation xml:lang="ru">Reddy H.L., Dayan A.D., Cavagnaro J., et al. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation // Transfus Med Rev. 2008. Vol. 22, No. 2. P. 133–153. DOI: 10.1016/j.tmrv.2007.12.003</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">Khan YA, Kashiwabuchi RT, Martins SA, et al. Riboflavin and ultraviolet light а therapy as an adjuvant treatment for medically refractive Acanthamoeba keratitis. Ophthalmology. 2011;118(2): 324–331. DOI: 10.1016/j.ophtha.2010.06.041</mixed-citation><mixed-citation xml:lang="ru">Khan Y.A., Kashiwabuchi R.T., Martins S.A., et al. Riboflavin and ultraviolet light a therapy as an adjuvant treatment for medically refractive Acanthamoeba keratitis // Ophthalmology. 2011. Vol. 118, No. 2. P. 324–331. DOI: 10.1016/j.ophtha.2010.06.041</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">Garduño-Vieyra L, Gonzalez-Sanchez CR, Hernandez-Da Mota SE. Ultraviolet — a light and riboflavin therapy for Acanthamoeba keratitis. Case Rep Ophthalmol. 2011;2(2):291–295. DOI: 10.1159/000331707</mixed-citation><mixed-citation xml:lang="ru">Garduño-Vieyra L., Gonzalez-Sanchez C.R., Hernandez-Da Mota S.E. Ultraviolet — a light and riboflavin therapy for Acanthamoeba keratitis // Case Rep Ophthalmol. 2011. Vol. 2, No. 2. P. 291–295. DOI: 10.1159/000331707</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">Berra M, Galperin G, Boscaro G, et al. Treatment of Acanthamoeba keratitis by corneal cross-linking. Cornea. 2013;32(2):174–178. DOI: 10.1097/ICO.0b013e31825cea99</mixed-citation><mixed-citation xml:lang="ru">Berra M., Galperin G., Boscaro G., et al. Treatment of Acanthamoeba keratitis by corneal cross-linking // Cornea. 2013. Vol. 32, No. 2. P. 174–178. DOI: 10.1097/ICO.0b013e31825cea99</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">Del Buey MA, Cristobal JA, Casas P, et al. Evaluation of in vitro efficacy of combined riboflavin and ultraviolet A for Acanthamoeba isolates. Am J Ophthalmol. 2012;153(3):399–404. DOI: 10.1016/j.ajo.2011.07.025</mixed-citation><mixed-citation xml:lang="ru">Del Buey M.A., Cristobal J.A., Casas P., et al. Evaluation of in vitro efficacy of combined riboflavin and ultraviolet A for Acanthamoeba isolates // Am J Ophthalmol. 2012. Vol. 153, No. 3. P. 399–404. DOI: 10.1016/j.ajo.2011.07.025</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">Lamy R, Chan E, Good SD, et al. Riboflavin and ultraviolet A as adjuvant treatment against Acanthamoeba cysts. Clin Exp Ophthalmol. 2016;44(3):181–187. DOI: 10.1111/ceo.12644</mixed-citation><mixed-citation xml:lang="ru">Lamy R., Chan E., Good S.D., et al. Riboflavin and ultraviolet A as adjuvant treatment against Acanthamoeba cysts // Clin Exp Ophthalmol. 2016. Vol. 44, No. 3. P. 181–187. DOI: 10.1111/ceo.12644</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">Kashiwabuchi RT, Carvalho FRS, Khan YA, et al. Assessing efficacy of combined riboflavin and UV-A light (365 nm) treatment of Acanthamoeba trophozoites. Investig Ophthalmol Vis Sci. 2011;52(13):9333–9338. DOI: 10.1167/iovs.11-8382</mixed-citation><mixed-citation xml:lang="ru">Kashiwabuchi R.T., Carvalho F.R.S., Khan Y.A., et al. Assessing efficacy of combined riboflavin and UV-A light (365 nm) treatment of Acanthamoeba trophozoites // Investig Ophthalmol Vis Sci. 2011. Vol. 52, No. 13. P. 9333–9338. DOI: 10.1167/iovs.11-8382</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">Price MO, Price FW Jr. Corneal cross-linking in the treatment of corneal ulcers. Curr Opin Ophthalmol. 2016;27(3):250–255. DOI: 10.1097/ICU.0000000000000248</mixed-citation><mixed-citation xml:lang="ru">Price M.O., Price F.W. Jr. Corneal cross-linking in the treatment of corneal ulcers // Curr Opin Ophthalmol. 2016. Vol. 27, No. 3. P. 250–255. DOI: 10.1097/ICU.0000000000000248</mixed-citation></citation-alternatives></ref><ref id="B17"><label>17.</label><citation-alternatives><mixed-citation xml:lang="en">Kasparova EA, Zajcev AV, Kasparova EA, Kasparov AA. Micro diathermocoagulation in the treatment of infectious corneal ulcers. Ophthalmology in Russia. 2016;13(3):157–162. (In Russ.) DOI: 10.18008/1816-5095-2016-3-157-162</mixed-citation><mixed-citation xml:lang="ru">Каспарова Е.А., Зайцев А.В., Каспарова Е.А., Каспаров А.А. Микродиатермокоагуляция в лечении инфекционных язв роговицы // Офтальмология. 2016. Т. 13, № 3. С. 157–162. DOI: 10.18008/1816-5095-2016-3-157-162</mixed-citation></citation-alternatives></ref><ref id="B18"><label>18.</label><citation-alternatives><mixed-citation xml:lang="en">Patent RU No. 2732696/ 2020 Sept 21. Nespor Radek (CZ). A portable device used primarily for cauterization and drying by spark for cauterization and drying by means of a spark discharge. Moscow: FIPS. (In Russ.)</mixed-citation><mixed-citation xml:lang="ru">Патент РФ на изобретение № 2732696/ 21.09.2020. Неспор Радек (CZ). Портативное устройство, используемое главным образом для прижигания и высушивания посредством искрового разряда. Москва: ФИПС.</mixed-citation></citation-alternatives></ref></ref-list></back></article>
